News
Weight Loss In a Pill Will Make Eli Lilly a $1 Trillion Stock
Pharmaceutical giant Eli Lilly (LLY) surged 14% last week to $840 per share following positive Phase 3 trial results for its oral weight-loss drug, orforglipron. With a market cap of $796 billion, LLY is the world’s most valuable healthcare company, and its trajectory suggests it could reach $1,000 per share or more by year-end 2025.
Eli Lilly's robust sales for Mounjaro and Zepbound along with its positive outlook for 2025 also work in its favor. Click ...
Shares fell after Eli Lilly announced results of a new pill that could rival the weight-loss potential of the Danish giant’s ...
2h
Eli Lilly gains analyst support after Phase 3 success. Bullish forecasts for obesity dominance and key earnings are set for ...
5don MSN
We recently published a list of 15 Best Blue Chip Stocks to Buy According to Billionaires. In this article, we are going to ...
Let's look at why this news could be a game-changer for Eli Lilly and its stock.
Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...
Citi analyst Geoff Meacham maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today. The company’s shares closed last ...
Pharmaceutical companies—including Eli Lilly and Novo Nordisk, which currently dominate the obesity market—have been testing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback